Nathalie M. Vandecan

University of Michigan–Ann Arbor — United States

Medicine · Health Sciences

6h-index95citations25works3.62yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Bladder and Urothelial Cancer Treatments(7), Computational Drug Discovery Methods(5), Chronic Myeloid Leukemia Treatments(5), Bioinformatics and Genomic Networks(4), Quinazolinone synthesis and applications(4)

Publications25 total

Abstract 491: Molecular correlates of drug response to identify novel therapeutic combinations in triple-negative breast cancer
Cancer Research·2025
Integrative Drug Screening and Multiomic Characterization of Patient-derived Bladder Cancer Organoids Reveal Novel Molecular Correlates of Gemcitabine Response
European Urology·2024· 18 cited
Abstract A009: Integrative drug screening and multi-omic characterization of patient-derived bladder cancer organoids reveals novel molecular correlates of chemotherapy response
Clinical Cancer Research·2024
Abstract PO2-16-01: Molecular correlates of drug response to guide therapy in triple-negative breast cancer
Cancer Research·2024
Abstract 4548: Discovering novel ALK-lung carcinoma therapeutic strategies by identifying combinations with Alectinib from ALK-positive lung carcinoma cell lines
Cancer Research·2024
Selective and Potent PROTAC Degraders of c-Src Kinase
ACS Chemical Biology·2023· 12 citedOpen Access
136P Molecular correlates of drug response to guide therapy in TNBC
ESMO Open·2023Open Access
Selective and potent PROTAC degraders of c-Src kinase
2023· 1 citedOpen Access
Reply to Correspondence on “Synergy and Antagonism between Allosteric and Active‐Site Inhibitors of Abl Tyrosine Kinase”
Angewandte Chemie International Edition·2022· 3 citedOpen Access
Reply to Correspondence on “Synergy and Antagonism between Allosteric and Active‐Site Inhibitors of Abl Tyrosine Kinase”
Angewandte Chemie·2022Open Access
Abstract 3072: Functional assays of drug sensitivity in real-time from patient material for precision oncology in bladder cancer
Cancer Research·2022
Insights into the modular design of kinase inhibitors and application to Abl and Axl
RSC Medicinal Chemistry·2021· 4 citedOpen Access
Synergy and Antagonism between Allosteric and Active‐Site Inhibitors of Abl Tyrosine Kinase
Angewandte Chemie International Edition·2021· 26 citedOpen Access
Synergy and Antagonism between Allosteric and Active‐Site Inhibitors of Abl Tyrosine Kinase
Angewandte Chemie·2021· 6 citedOpen Access
Abstract 1194: MEK inhibition in combination with PI3K/AKT/MTOR is a promising therapeutic in basal bladder cancer
Cancer Research·2021
Abstract 1187: Optimizing gemcitabine in metastatic TNBC by rational PI3K/AKT combination
Cancer Research·2021· 1 cited
MEK is a promising target in the basal subtype of bladder cancer
Oncotarget·2020· 11 citedOpen Access
Abstract 38: Molecular determinants of drug response in TNBC cell lines
Clinical Cancer Research·2020
PD47-11 RAPID ORGANOID DEVELOPMENT, DRUG SCREENING, AND NEOADJUVANT CHEMOTHERAPY RESPONSE PREDICTION FOR PATIENTS WITH LOCALLY-ADVANCED BLADDER CANCER
The Journal of Urology·2020Open Access
Rapid organoid development, drug screening, and neoadjuvant chemotherapy response prediction for patients with locally advanced bladder cancer.
Journal of Clinical Oncology·2020
page 1 of 2Next →

Frequent Co-authors

Matthew B. Soellner(23), Sofía D. Merajver(20), Nathan Merrill(16), Peter Ulintz(14), Liwei Bao(10), Aaron M. Udager(8), Athena Apfel(7), Xu Cheng(7), Daniel A. Bochar(6), Habib Serhan(6), Aki Morikawa(6), Taylor K. Johnson(5), Sameer Phadke(5), Samuel D. Kaffenberger(5), Laura Goo(5), Todd M. Morgan(5), Eric J. Lachacz(5), Jessica Furtado(4), Michael P. Agius(4), Zhaoping Qin(4)